ArticleBMC cardiovascular disorders2025
Impact of metabolic syndrome on clinical characteristics and one-year outcomes of patients undergoing primary percutaneous coronary intervention: a propensity score-matched comparison.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of MetS on Long-Term Prognosis Among STEMI Patients Treated with pPCI-Ten-Year Follow-Up Study.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS) is a set of symptoms, including insulin resistance, high blood sugar, and abdominal obesity, that increases the risk of cardiovascular diseases. This syndrome is prevalent in acute coronary syndrome (ACS), comprising patients with acute myocardial infarction (AMI). This study evaluated the prognosis of AMI patients who underwent primary PCI in two groups with and without MetS.
methodsThis retrospective study was performed on ST-segment elevation myocardial infarction (STEMI) patients referred to the emergency department of Tehran Heart Center from 2012 to 2020 who underwent primary PCI. Patients were divided into MetS and non-MetS according to the International Diabetes Federation (IDF) criteria. Clinical and laboratory characteristics were compared between the two groups.
resultsTwo thousand, six hundred fifty-one patients were included, and 1850 patients (70%) had MetS. The mean age of patients with MetS compared to non-MetS showed no significant difference (60.16 vs 59.37 years, P-value = 0.053). In both groups, the majority were men. Forty-seven in-hospital deaths occurred, with no significant difference regarding the presence of MetS. Two hundred-six deaths happened during the one-year follow-up, without a significant difference between the two groups. Two hundred-sixteen MACEs were observed in one year, which was not significantly different between patients with and without MetS.
conclusionIn-hospital mortality, one-year death, and one-year MACCE were not associated with MetS in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.